Home > Healthcare > Pharmaceuticals > Drug Delivery > Sustained-Release Excipients Market

Sustained-Release Excipients Market Share

Report ID: GMI12657
Published Date: Dec 2024
Report Format: PDF

Download Free Sample

Sustained-Release Excipients Market Share

The market is highly competitive, driven by increasing demand for effective and innovative drug delivery solutions across the pharmaceutical sector. Established companies dominate the market with extensive portfolios of excipients, including polymers, gelatin, and sugars, which are essential for developing sustained-release formulations. However, emerging players are gaining traction by introducing cost-effective and user-friendly excipients tailored for specific applications in pharmaceuticals. Technological advancements, such as targeted delivery systems and microencapsulation techniques, are significant differentiators that enhance the precision and efficacy of drug release profiles.

In this evolving landscape, continuous innovation in excipient formulation, regulatory compliance, and integration with advanced drug delivery technologies is crucial to meet the growing need for patient-centric healthcare solutions and to maintain high standards of safety and effectiveness in sustained-release formulations.

Sustained-Release Excipients Market Companies

Prominent players operating in the sustained-release excipients industry include:

BASF
Ashland Global
Colorcon
Croda International
DFE Pharma
Eastman
Evonik Industries
FMC Corporation
Gattefosse
International Flavors & Fragrances
JRS Pharma
Merck
Roquette
Seppic
Shin-Etsu Chemical

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global sustained-release excipients industry was valued at USD 1.4 billion in 2024 and is projected to grow at an 8.3% CAGR from 2025 to 2034, driven by the increasing prevalence of chronic diseases and rising demand for controlled-release formulations.

The polymers segment generated USD 435.2 million in revenue in 2024, as their versatility allows for tailored drug release profiles, meeting specific therapeutic needs.

The U.S. sustained-release excipients market is expected to reach USD 967.4 million by 2034, driven by a high prevalence of chronic diseases and the need for formulations that improve patient compliance.

Key players in the market include BASF, Ashland Global, Colorcon, Croda International, DFE Pharma, Eastman, Evonik Industries, FMC Corporation, Gattefosse, International Flavors & Fragrances, and JRS Pharma.